This has been supported by the previous literature, where topical steroids have been found to exert beneficial effects in reducing MCP-1 levels [33] in patients with dry eyes, reversing the cellularity (i.e., macrophages, lymphocytes, mast cells) of conjunctival tissues [26] and decreasing conjunctival inflammation [27]. The gene discussed is CCL2; the disease is dry eye syndrome.